SEC Form 4 · accession 0000914190-26-000100
Envoy Medical, Inc. · COCH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Brent T. Lucas
Officer — Chief Executive Officer · Director
Period of report
Jun 19, 2026
Accepted (ET)
Jun 23, 2026 · 6:28 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001840877
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common Stock | holding | — | — | — | 329,946 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $0.634 | Jun 19, 2026 | A | 1,000,000 | A | — | Jun 19, 2036 | Class A Common Stock | 1,000,000 | 1,000,000 | D |
| Restricted Stock UnitsF7,F8 | — | Jun 19, 2026 | A | 1,000,000 | A | — | Jun 18, 2030 | Class A Common Stock | 1,000,000 | 1,000,000 | D |
| Stock Option (right to buy)F1 | $2.40 | holding | — | — | — | — | Oct 15, 2033 | Class A Common Stock | 879,749 | 879,749 | D |
| Stock Option (right to buy)F2 | $0.53 | holding | — | — | — | — | Feb 5, 2036 | Class A Common Stock | 200,000 | 200,000 | D |
| Warrant (right to buy)F4 | $11.50 | holding | — | — | — | — | Sep 29, 2028 | Class A Common Stock | 110,987 | 110,987 | D |
| Warrant (right to buy)F4,F5 | $0.40 | holding | — | — | — | — | — | Class A Common Stock | 37,500 | 37,500 | D |
| Warrant (right to buy)F4,F6 | $0.40 | holding | — | — | — | — | — | Class A Common Stock | 62,500 | 62,500 | D |
Explanation of responses
- F1Options to purchase 659,811 shares vest on 10/15/2023, and 219,938 shares vest pro rata on the 15th of each month thereafter for 36 consecutive months.
- F2Options to purchase 50,000 shares vest on 2/5/2027, and 150,000 shares vest pro rata on the 5th of each month thereafter for 36 consecutive months.
- F3Options to purchase 250,000 shares vest on 6/19/27, and 750,000 shares vest pro rata on the 19th of each month thereafter for 36 consecutive months.
- F4Fully exercisable.
- F5The Series A-1 Warrants expire on the earlier of (i) two years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has submitted a Premarket Approval Application to the Food and Drug Administration (FDA) for its Acclaim CI Device.
- F6The Series A-2 Warrants expire on the earlier of (i) five years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has received FDA approval for its Acclaim CI Device.
- F7Each restricted stock unit represents a contingent right to receive one share of Envoy Medical, Inc. Class A Common Stock.
- F8All restricted stock units subject to the RSU Award Grant Notice dated June 19, 2026, will vest as of the date of the official notification by the U.S. Food and Drug Administration (FDA) that it has granted approval (including approval with conditions) for its Acclaim cochlear implant, provided that such announcement occurs during the performance period beginning June 19, 2026 and ending on June 18, 2030.